Flomics

Barcelona, Spain

CancerPrevention

Flomics introduces a liquid biopsy with cell-free long RNAs (cfRNAs) for the early detection of complex diseases, such as cancer. From a simple blood draw, an asymptomatic individual has the chance to be screened in a minimally invasive way and to understand if he/she needs to move on to more complex exploratory analysis. This is particularly important for individuals with >50 years of age, familiars of cancer patients or high-risk populations, e.g. smokers. In order to help in the current pandemic we are living in, Flomics has joined forces with international biotech partners, specialized in Next Generation Sequencing tests, to develop a cloud-based data analysis solution for COVID19 detection and research. Combining the unique features of the different experimental sequencing kits available for SARS-CoV-2 detection (either metagenomics or ampicon based), we maximize the information extracted from each single experiment performed in a reliable, sensitive and automated way. Our platform helps hospitals, clinics and research laboratories in transforming raw data into interpretable clinical information that will help manage this pandemic, without the need for computational infrastructures or bioinformatics expertise.